Last 7 days
-10.3%
Last 30 days
-14.4%
Last 90 days
-12.0%
Trailing 12 Months
34.5%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-02 | Wygant Jonathan | sold (taxes) | -33,294 | 26.7 | -1,247 | vp, chief accounting officer |
2023-09-02 | Stapley Marc | sold (taxes) | -85,546 | 26.7 | -3,204 | chief executive officer |
2023-09-02 | Chambers Rebecca | sold (taxes) | -97,508 | 26.7 | -3,652 | chief financial officer |
2023-09-02 | McGuire Annie | sold (taxes) | -46,164 | 26.7 | -1,729 | svp, general counsel |
2023-09-02 | Leite John | sold (taxes) | -59,327 | 26.7 | -2,222 | chief commercial officer-clia |
2023-07-19 | JONES EVAN/ FA | sold | -93,232 | 30.1723 | -3,090 | - |
2023-07-19 | JONES EVAN/ FA | sold | -25,257 | 30.1398 | -838 | - |
2023-07-18 | JONES EVAN/ FA | sold | -224,616 | 30.1863 | -7,441 | - |
2023-07-18 | BISHOP JOHN L | acquired | 63,700 | 6.37 | 10,000 | - |
2023-07-18 | JONES EVAN/ FA | sold | -70,089 | 30.1591 | -2,324 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 21.63 | 1,265,000 | 4,514,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 47.00 | 382 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -4.17 | 31,533 | 365,163 | 0.09% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | 31,053 | 249,504 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | 34,000 | 34,000 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.22 | 233,622 | 2,233,820 | -% |
2023-08-21 | VitalStone Financial, LLC | unchanged | - | -1,000 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.98 | 59,534 | 446,865 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 13.97 | 227,000 | 979,000 | 0.01% |
2023-08-18 | Legato Capital Management LLC | added | 36.37 | 422,262 | 1,179,590 | 0.16% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jun 09, 2023 | wellington management group llp | 10.01% | 7,248,889 | SC 13G/A | |
Feb 09, 2023 | william blair investment management, llc | 0.8% | 558,384 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.55% | 6,852,657 | SC 13G/A | |
Feb 06, 2023 | state street corp | 5.80% | 4,159,331 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 9.25% | 6,636,543 | SC 13G/A | |
Jan 25, 2023 | blackrock inc. | 9.1% | 6,534,569 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 4.39% | 3,121,103 | SC 13G/A | |
Feb 10, 2022 | invesco ltd. | 5.8% | 4,114,031 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.57% | 8,222,281 | SC 13G/A | |
Feb 04, 2022 | artisan partners limited partnership | 7.0% | 4,956,409 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 06, 2023 | 3 | Insider Trading | |
Sep 06, 2023 | 4 | Insider Trading | |
Sep 06, 2023 | 4 | Insider Trading | |
Sep 06, 2023 | 4 | Insider Trading | |
Sep 06, 2023 | 4 | Insider Trading | |
Sep 06, 2023 | 4 | Insider Trading | |
Aug 09, 2023 | 10-Q | Quarterly Report | |
Aug 08, 2023 | 8-K | Current Report | |
Jul 24, 2023 | 4 | Insider Trading | |
Jul 19, 2023 | 144 | Notice of Insider Sale Intent |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 269.9B | 56.0B | 3.85% | 7.89% | 31.08 | 4.82 | -2.31% | -31.27% |
VRTX | 90.1B | 9.5B | -0.31% | 22.07% | 26.78 | 9.48 | 13.83% | 5.33% |
REGN | 88.3B | 12.7B | -1.90% | 19.84% | 20.53 | 6.97 | -10.94% | -24.40% |
INCY | 13.0B | 3.5B | -10.13% | -13.81% | 35.41 | 3.69 | 5.81% | -61.22% |
MID-CAP | ||||||||
NTRA | 5.2B | 931.0M | -16.86% | -0.76% | -10.21 | 5.61 | 28.69% | 11.08% |
ARWR | 2.9B | 256.2M | -4.82% | -13.52% | -16.11 | 11.39 | 2.51% | -17.66% |
SMALL-CAP | ||||||||
VCYT | 1.6B | 328.6M | -14.37% | 34.47% | -56.17 | 4.97 | 22.46% | 40.27% |
CSTL | 442.5M | 167.5M | -10.46% | -33.92% | -4.98 | 2.64 | 52.01% | -99.69% |
CDNA | 413.7M | 309.3M | -12.66% | -52.30% | -4.93 | 1.34 | -1.76% | -21.01% |
ORGO | 317.8M | 457.3M | -9.02% | -24.14% | 31.63 | 0.69 | -0.61% | -85.93% |
CELC | 220.2M | - | -2.83% | 14.20% | -4.49 | - | - | -59.74% |
NVTA | 176.8M | 493.9M | -33.66% | -73.83% | -0.22 | 0.36 | -1.39% | 74.28% |
OPGN | 1.6M | 2.8M | 29.38% | -44.90% | -0.04 | 0.57 | -31.25% | -41.90% |
17.2%
17.5%
-10.7%
100%
67.7%
45.4%
Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 5.6% | 328,633,000 | 311,175,000 | 296,536,000 | 283,575,000 | 268,353,000 | 250,594,000 | 219,514,000 | 186,714,000 | 157,465,000 | 123,064,000 | 117,483,000 | 112,677,000 | 112,529,000 | 121,961,000 | 120,368,000 | 116,388,000 | 108,881,000 | 101,496,000 | 92,008,000 | 85,854,000 | 79,907,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36,077,000 | 35,108,000 | 34,255,000 | 33,724,000 | 33,078,000 | 32,143,000 | 31,051,000 |
Costs and Expenses | 4.3% | 362,282,000 | 347,506,000 | 337,617,000 | 331,569,000 | 323,348,000 | 302,330,000 | 301,417,000 | 264,356,000 | 222,492,000 | 191,668,000 | 152,872,000 | 148,191,000 | 145,740,000 | 147,221,000 | 135,495,000 | 126,375,000 | 121,409,000 | 116,841,000 | 114,241,000 | 111,074,000 | 107,191,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114,241,000 | - | - |
S&GA Expenses | 1.8% | 101,691,000 | 99,936,000 | 97,560,000 | 95,645,000 | 91,637,000 | 87,298,000 | 79,840,000 | 70,777,000 | 60,062,000 | 51,101,000 | 52,389,000 | 53,423,000 | 55,556,000 | 58,798,000 | 53,691,000 | 49,574,000 | 46,567,000 | 42,247,000 | 41,313,000 | 40,292,000 | 38,096,000 |
R&D Expenses | 7.2% | 47,370,000 | 44,206,000 | 40,603,000 | 39,568,000 | 36,801,000 | 33,673,000 | 29,843,000 | 24,177,000 | 20,213,000 | 18,133,000 | 17,204,000 | 17,061,000 | 16,662,000 | 15,823,000 | 14,851,000 | 13,533,000 | 13,309,000 | 14,580,000 | 14,820,000 | 14,897,000 | 14,524,000 |
EBITDA | 100.0% | - | -4,003,000 | -10,490,000 | -18,527,000 | -25,423,000 | -26,846,000 | -61,998,000 | -63,099,000 | -55,731,000 | -60,107,000 | -26,736,000 | -28,364,000 | -39,046,000 | -41,291,000 | -7,806,000 | - | - | - | - | - | - |
EBITDA Margin | 100.0% | - | -0.01 | -0.04 | -0.07 | -0.09 | -0.11 | -0.28 | -0.34 | -0.35 | -0.49 | -0.23 | -0.25 | -0.35 | -0.34 | -0.06 | - | - | - | - | - | - |
Interest Expenses | - | - | - | 9,000 | - | - | 63,000 | 9,000 | 73,000 | 128,000 | 130,000 | 13,000 | -89,000 | -86,000 | 84,000 | 332,000 | 1,132,000 | 1,572,000 | 1,818,000 | 1,963,000 | 3,945,000 | 4,262,000 |
Earnings Before Taxes | 4.6% | -28,684,000 | -30,054,000 | -36,427,000 | -44,254,000 | -50,858,000 | -50,401,000 | -81,600,000 | -78,376,000 | -67,021,000 | -68,856,000 | -34,909,000 | -35,820,000 | -45,482,000 | -46,864,000 | -12,599,000 | - | - | - | - | - | - |
EBT Margin | 100.0% | - | -0.10 | -0.12 | -0.16 | -0.19 | -0.20 | -0.37 | -0.42 | -0.43 | -0.56 | -0.30 | -0.32 | -0.40 | -0.38 | -0.10 | - | - | - | - | - | - |
Net Income | 3.7% | -29,060,000 | -30,190,000 | -36,560,000 | -43,244,000 | -48,650,000 | -48,156,000 | -75,563,000 | -73,079,000 | -63,074,000 | -65,061,000 | -34,909,000 | -34,323,000 | -30,929,000 | -22,398,000 | -12,599,000 | -8,246,000 | -11,985,000 | -15,739,000 | -22,999,000 | -28,333,000 | -30,913,000 |
Net Income Margin | 100.0% | - | -0.10 | -0.12 | -0.15 | -0.18 | -0.19 | -0.34 | -0.39 | -0.40 | -0.53 | -0.30 | -0.30 | -0.27 | -0.18 | -0.10 | - | - | - | - | - | - |
Free Cashflow | -100.0% | - | 7,146,000 | -1,014,000 | -1,281,000 | -9,798,000 | -6,565,000 | -36,997,000 | -43,229,000 | -38,907,000 | -48,339,000 | -12,548,000 | -13,231,000 | -16,136,000 | -10,178,000 | -5,988,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 0.3% | 1,161 | 1,157 | 1,156 | 1,126 | 1,144 | 1,174 | 1,188 | 1,186 | 1,027 | 1,025 | 457 | 454 | 257 | 267 | 275 | 260 | 252 | 124 | 121 | 119 | 65.00 |
Current Assets | 3.2% | 259 | 252 | 249 | 239 | 235 | 238 | 243 | 229 | 371 | 362 | 376 | 370 | 173 | 181 | 188 | 228 | 220 | 91.00 | 97.00 | 95.00 | 42.00 |
Cash Equivalents | 7.4% | 191 | 178 | 154 | 170 | 154 | 164 | 174 | 165 | 328 | 325 | 349 | 346 | 148 | 154 | 160 | 196 | 193 | 68.00 | 79.00 | 78.00 | 24.00 |
Inventory | -13.0% | 12.00 | 13.00 | 14.00 | 14.00 | 15.00 | 12.00 | 11.00 | 10.00 | 7.00 | 6.00 | 5.00 | 4.00 | 7.00 | 6.00 | 7.00 | 7.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Net PPE | - | - | - | - | - | - | - | - | - | 12.00 | 11.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 |
Goodwill | -0.1% | 699 | 700 | 696 | 677 | 690 | 704 | 708 | 714 | 472 | 475 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 3.3% | 78.00 | 76.00 | 81.00 | 78.00 | 80.00 | 88.00 | 91.00 | 79.00 | 56.00 | 51.00 | 36.00 | 31.00 | 31.00 | 37.00 | 36.00 | 29.00 | 28.00 | 40.00 | 41.00 | 40.00 | 40.00 |
Current Liabilities | 3.9% | 58.00 | 56.00 | 63.00 | 58.00 | 59.00 | 63.00 | 64.00 | 50.00 | 36.00 | 33.00 | 17.00 | 14.00 | 13.00 | 19.00 | 17.00 | 17.00 | 15.00 | 14.00 | 13.00 | 10.00 | 10.00 |
LT Debt, Current | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 13.00 | 24.00 | 25.00 | 25.00 |
Shareholder's Equity | 0.1% | 1,083 | 1,081 | 1,075 | 1,048 | 1,064 | 1,085 | 1,097 | 1,107 | 971 | 974 | 421 | 423 | 226 | 230 | 239 | 231 | 224 | 84.00 | 80.00 | 79.00 | 26.00 |
Retained Earnings | -2.1% | -410 | -401 | -393 | -389 | -381 | -371 | -357 | -346 | -332 | -323 | -281 | -273 | -269 | -258 | -246 | -239 | -238 | -236 | -234 | -230 | -226 |
Additional Paid-In Capital | 0.7% | 1,521 | 1,510 | 1,500 | 1,492 | 1,483 | 1,477 | 1,469 | 1,462 | 1,304 | 1,298 | 703 | 696 | 496 | 489 | 486 | 470 | 463 | 320 | 314 | 310 | 252 |
Shares Outstanding | 0.4% | 73.00 | 72.00 | 72.00 | 72.00 | 71.00 | 71.00 | 71.00 | 70.00 | 67.00 | 63.00 | 58.00 | 55.00 | 50.00 | 50.00 | 50.00 | 49.00 | 46.00 | 41.00 | 37.00 | 39.00 | 34.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 119.7% | 31.00 | 14.00 | 8.00 | 6.00 | -2.18 | 0.00 | -31.62 | -37.81 | -34.66 | -44.97 | -9.71 | -10.18 | -13.49 | -7.52 | -3.23 | -6.25 | -6.47 | -7.12 | -13.52 | -18.11 | -21.43 |
Share Based Compensation | 15.8% | 33.00 | 28.00 | 27.00 | 27.00 | 27.00 | 25.00 | 23.00 | 19.00 | 15.00 | 14.00 | 13.00 | 12.00 | 12.00 | 11.00 | 10.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 |
Cashflow From Investing | 197.5% | 3.00 | -2.85 | -29.39 | -2.57 | -176 | -166 | -739 | -740 | -576 | -578 | -3.84 | -44.05 | -42.64 | -42.65 | -42.73 | -2.09 | -2.52 | -2.40 | -1.87 | -1.72 | -1.79 |
Cashflow From Financing | 14.8% | 4.00 | 3.00 | 3.00 | 4.00 | 5.00 | 7.00 | 596 | 599 | 793 | 795 | 204 | 204 | 11.00 | 135 | 127 | 126 | 178 | 50.00 | 59.00 | 56.00 | 0.00 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Total revenue | $ 90,322 | $ 72,864 | $ 172,744 | $ 140,647 |
Operating expenses: | ||||
Research and development | 12,541 | 9,377 | 25,310 | 18,543 |
Selling and marketing | 25,756 | 24,001 | 51,886 | 47,755 |
General and administrative | 25,047 | 19,798 | 47,510 | 40,710 |
Intangible asset amortization | 5,341 | 5,391 | 10,670 | 10,877 |
Total operating expenses | 98,373 | 83,597 | 191,293 | 166,628 |
Loss from operations | (8,051) | (10,733) | (18,549) | (25,981) |
Other income (loss), net | (226) | 1,086 | 2,181 | 1,870 |
Loss before income taxes | (8,277) | (9,647) | (16,368) | (24,111) |
Income tax expense (benefit) | 125 | (115) | 125 | (118) |
Net loss | $ (8,402) | $ (9,532) | $ (16,493) | $ (23,993) |
Net loss per common share, basic (in USD per share) | $ (0.12) | $ (0.13) | $ (0.23) | $ (0.34) |
Net loss per common share, diluted (in USD per share) | $ (0.12) | $ (0.13) | $ (0.23) | $ (0.34) |
Shares used to compute net loss per common share, basic (in shares) | 72,478,662 | 71,476,966 | 72,327,897 | 71,354,002 |
Shares used to compute net loss per common share, diluted (in shares) | 72,478,662 | 71,476,966 | 72,327,897 | 71,354,002 |
Testing revenue | ||||
Revenue: | ||||
Total revenue | $ 81,749 | $ 59,718 | $ 154,145 | $ 115,698 |
Operating expenses: | ||||
Cost of revenue | 23,333 | 18,584 | 42,981 | 36,107 |
Product revenue | ||||
Revenue: | ||||
Total revenue | 4,011 | 3,108 | 7,903 | 6,087 |
Operating expenses: | ||||
Cost of revenue | 2,315 | 1,646 | 4,477 | 3,221 |
Biopharmaceutical and other revenue | ||||
Revenue: | ||||
Total revenue | 4,562 | 10,038 | 10,696 | 18,862 |
Operating expenses: | ||||
Cost of revenue | $ 4,040 | $ 4,800 | $ 8,459 | $ 9,415 |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 191,142,000 | $ 154,247,000 |
Short-term investments | 0 | 24,605,000 |
Accounts receivable | 42,365,000 | 44,021,000 |
Supplies and inventory | 11,572,000 | 14,294,000 |
Prepaid expenses and other current assets | 14,401,000 | 11,469,000 |
Total current assets | 259,480,000 | 248,636,000 |
Property, plant and equipment, net | 18,510,000 | 17,702,000 |
Right-of-use assets, operating leases | 12,455,000 | 13,160,000 |
Intangible assets, net | 164,744,000 | 174,866,000 |
Goodwill | 698,920,000 | 695,891,000 |
Restricted cash | 889,000 | 749,000 |
Other assets | 6,116,000 | 5,418,000 |
Total assets | 1,161,114,000 | 1,156,422,000 |
Current liabilities: | ||
Accounts payable | 12,895,000 | 11,911,000 |
Accrued liabilities | 34,427,000 | 37,774,000 |
Current portion of deferred revenue | 2,378,000 | 2,613,000 |
Current portion of acquisition-related contingent consideration | 3,359,000 | 6,060,000 |
Current portion of operating lease liabilities | 4,973,000 | 4,070,000 |
Current portion of other liabilities | 119,000 | 186,000 |
Total current liabilities | 58,151,000 | 62,614,000 |
Deferred tax liabilities | 4,707,000 | 4,531,000 |
Acquisition-related contingent consideration, net of current portion | 4,855,000 | 2,498,000 |
Operating lease liabilities, net of current portion | 9,891,000 | 10,648,000 |
Other liabilities | 792,000 | 931,000 |
Total liabilities | 78,396,000 | 81,222,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 125,000,000 shares authorized, 72,643,156 and 71,959,454 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 73,000 | 72,000 |
Additional paid-in capital | 1,520,638,000 | 1,500,191,000 |
Accumulated deficit | (410,210,000) | (393,717,000) |
Accumulated other comprehensive loss | (27,783,000) | (31,346,000) |
Total stockholders’ equity | 1,082,718,000 | 1,075,200,000 |
Total liabilities and stockholders’ equity | $ 1,161,114,000 | $ 1,156,422,000 |